Insmed Share Price Today
(NASDAQ: INSM)

Name: Insmed Share Price Today (NASDAQ: INSM) - Insmed Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Insmed share price is $77.55 & ₹6,744.45 as on 6 Mar 2025, 2.30 'hrs' IST

$77.55

▲

0.34

(0.44%)

Market is closed - opens 8 PM, 06 Mar 2025

View live Insmed share price in Dollar and Rupees. Guide to invest in Insmed stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Insmed, along with analyst recommendations, forecasts, and comprehensive financials.

Insmed share price movements

Today's Low: $76.50
Today's High: $78.17
$77.55
1.35%
Downside
Day's Volatility :2.14%
Upside
0.79%
52 Weeks Low: $21.92
52 Weeks High: $84.91
$77.55
71.73%
Downside
52 Weeks Volatility :74.18%
Upside
8.67%

Insmed (INSM) Returns

Period	Insmed Incorporated	Sector (Health Care)	Index (Russel 2000)
3 Months	2.95%	3.7%	0.0%
6 Months	6.36%	-2.8%	0.0%
1 Year	177.06%	2.5%	0.0%
3 Years	234.84%	12.9%	-11.6%

Insmed (INSM) Key Statistics

in dollars & INR

Previous Close	$77.21
Open	$77.0
Today's High	$78.17
Today's Low	$76.5
Market Capitalization	$14.0B
Today's Volume	$1.1M
52 Week High	$84.91
52 Week Low	$21.92
Revenue TTM	$363.7M
EBITDA	$-777.7M
Earnings Per Share (EPS)	$-5.57
Profit Margin	-251.24%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-890.75%

How to invest in Insmed Stock (INSM) from India?

It is very easy for Indian residents to invest directly in Insmed from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Insmed stock in both Indian Rupees (INR) and US Dollars (USD). Search for Insmed or INSM on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Insmed or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Insmed shares which would translate to 0.011 fractional shares of Insmed as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Insmed, in just a few clicks!

Returns in Insmed (INSM) for Indian investors in Rupees

The Insmed stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Insmed investment value today

Current value as on today

₹2,82,012

Returns

₹1,82,012

(+182.01%)

Returns from Insmed Stock

₹1,77,063 (+177.06%)

Dollar Returns

₹4,949 (+4.95%)

Indian investors sentiment towards Insmed (INSM)

Period: Feb 3, 2025 to Mar 5, 2025. Change in 30 Days versus previous period

Search interest for Insmed Stock from India on INDmoney has increased by 8% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Insmed

Vanguard Group Inc
10.07%
BlackRock Inc
8.86%
Darwin Global Management, Ltd.
7.16%
T. Rowe Price Associates, Inc.
7.02%
Capital Research & Mgmt Co - Division 3
3.93%
State Street Corp
3.37%

Analyst Recommendation on Insmed

Buy

95%Buy

4%Hold

0%Sell

Based on 23 Wall street analysts offering stock ratings for Insmed(by analysts ranked 0 to 5 stars)

Based on 23 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Insmed Stock (INSM)

What analysts predicted

Upside of 22.98%

Target:

$95.37

Current:

$77.55

Insights on Insmed Stock (Ticker Symbol: INSM)

Price Movement
In the last 1 year, INSM stock has moved up by 177.1%
Increasing Revenue
Revenue is up for the last 4 quarters, 75.5M → 104.44M (in $), with an average increase of 10.1% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, -220.52M → -235.54M (in $), with an average decrease of 6.8% per quarter

Insmed Technicals Summary

Sell

Neutral

Buy

Insmed is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Insmed (INSM) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Insmed Incorporated	-4.27%	6.36%	177.06%	234.84%	260.2%
Regeneron Pharmaceuticals, Inc.	-1.42%	-40.28%	-29.31%	11.08%	44.83%
Beone Medicines Ltd	17.63%	36.87%	64.37%	45.89%	71.3%
Vertex Pharmaceuticals Incorporated	1.94%	4.92%	19.37%	108.73%	123.83%
Alnylam Pharmaceuticals, Inc.	-8.03%	-0.89%	66.53%	52.9%	126.66%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Insmed Incorporated	NA	NA	0.0	-5.29	-8.91	-0.29	NA	1.59
Regeneron Pharmaceuticals, Inc.	17.86	17.86	1.01	43.09	0.16	0.07	0.01	273.57
Beone Medicines Ltd	NA	NA	NA	1.43	-0.19	-0.06	NA	31.22
Vertex Pharmaceuticals Incorporated	32.84	NA	1.34	18.07	-0.03	0.13	NA	63.87
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	0.57	-15.01	-0.03	NA	0.52

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Insmed Incorporated	Buy	$14.0B	260.2%	NA	-251.24%
Regeneron Pharmaceuticals, Inc.	Buy	$73.8B	44.83%	17.86	31.07%
Beone Medicines Ltd	NA	$29.1B	71.3%	NA	-16.92%
Vertex Pharmaceuticals Incorporated	Buy	$124.9B	123.83%	32.84	-4.86%
Alnylam Pharmaceuticals, Inc.	Buy	$31.4B	126.66%	NA	-12.37%

Insmed Dividend announcements

Insmed Earnings
Insmed’s price-to-earnings ratio stands at None

About Insmed

Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also devlops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; and phase 2 clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops gene therapy, a microdystrophin adeno-associated virus gene replacement therapy which is in phase 1 clinical trial for the treatment of Duchenne muscular dystrophy, as well as is in pre-clinical development for gene therapy, next generation DPP1 inhibitor, deimmunized therapeutic protein, and synthetic rescue. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.

Organization	Insmed
Employees	1271
CEO	Mr. William H. Lewis J.D., M.B.A.
Industry	Health Technology

Management People of Insmed

Name	Title
Mr. William H. Lewis J.D., M.B.A.	President, CEO & Chairman
Ms. Sara M. Bonstein M.B.A.	Chief Financial Officer
Mr. Roger Adsett M.B.A.	Chief Operating Officer
Mr. John Drayton Wise M.B.A.	Chief Commercial Officer
Dr. Martina Flammer M.B.A., M.D.	Chief Medical Officer
Mr. Brian K. Kaspar Ph.D.	Chief Scientific Officer
Ms. Eleanor Barisser	Associate Director of Investor Relations
Mr. Michael Alexander Smith J.D.	Chief Legal Officer & Corporate Secretary
Mandy Fahey	Vice President of Corporate Communications
Ms. S. Nicole Schaeffer M.B.A.	Chief People Strategy Officer

Important FAQs about investing in INSM Stock from India :

What is Insmed share price today?

Insmed share price today stands at $77.55, Open: $77.00 ; Previous Close: $77.21 ; High: $78.17 ; Low: $76.50 ; 52 Week High: $84.91 ; 52 Week Low: $21.92.

The stock opens at $77.00, after a previous close of $77.21. The stock reached a daily high of $78.17 and a low of $76.50, with a 52-week high of $84.91 and a 52-week low of $21.92.

Can Indians buy Insmed shares?

Yes, Indians can invest in the Insmed (INSM) from India.

With INDmoney, you can buy Insmed at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Insmed at zero transaction cost.

How can I buy Insmed shares from India?

It is very easy to buy Insmed from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Insmed (INSM) be purchased?

Yes, you can buy fractional shares of Insmed with INDmoney app.

What are the documents required to start investing in Insmed stocks?

To start investing in Insmed, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.